This company listing is no longer active
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Kazia Therapeutics Performance dei guadagni passati
Il passato criteri di controllo 0/6
Kazia Therapeutics's earnings have been declining at an average annual rate of -22%, while the Biotechs industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 9.8% per year.
Informazioni chiave
-22.0%
Tasso di crescita degli utili
6.4%
Tasso di crescita dell'EPS
Biotechs Crescita del settore | 9.6% |
Tasso di crescita dei ricavi | 9.8% |
Rendimento del capitale proprio | -169.8% |
Margine netto | -3,687,419.8% |
Ultimo aggiornamento sui guadagni | 30 Jun 2023 |
Aggiornamenti sulle prestazioni recenti
Recent updates
We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn
Jun 24We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn
Feb 24We Take A Look At Why Kazia Therapeutics Limited's (ASX:KZA) CEO Compensation Is Well Earned
Nov 03We Think Kazia Therapeutics (ASX:KZA) Can Easily Afford To Drive Business Growth
Sep 23We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth
May 04When Will Kazia Therapeutics Limited (ASX:KZA) Turn A Profit?
Mar 27Could The Kazia Therapeutics Limited (ASX:KZA) Ownership Structure Tell Us Something Useful?
Feb 28What Can We Learn About Kazia Therapeutics' (ASX:KZA) CEO Compensation?
Feb 01We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth
Jan 06Bullish: Analysts Just Made An Incredible Upgrade To Their Kazia Therapeutics Limited (ASX:KZA) Forecasts
Dec 11Kazia Therapeutics Limited (ASX:KZA): When Will It Breakeven?
Nov 26Ripartizione dei ricavi e delle spese
Come Kazia Therapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
---|---|---|---|---|
30 Jun 23 | 0 | -20 | 9 | 16 |
31 Mar 23 | 0 | -23 | 8 | 17 |
31 Dec 22 | 0 | -25 | 6 | 19 |
30 Sep 22 | 0 | -25 | 6 | 19 |
30 Jun 22 | 0 | -25 | 5 | 20 |
31 Mar 22 | 8 | -20 | 5 | 21 |
31 Dec 21 | 15 | -15 | 6 | 23 |
30 Sep 21 | 15 | -12 | 6 | 19 |
30 Jun 21 | 15 | -8 | 7 | 15 |
31 Mar 21 | 8 | -11 | 6 | 11 |
31 Dec 20 | 0 | -13 | 5 | 8 |
30 Sep 20 | 1 | -13 | 4 | 9 |
30 Jun 20 | 1 | -12 | 4 | 9 |
31 Mar 20 | 1 | -11 | 4 | 8 |
31 Dec 19 | 1 | -10 | 4 | 7 |
30 Sep 19 | 1 | -10 | 4 | 7 |
30 Jun 19 | 1 | -10 | 4 | 6 |
31 Mar 19 | 2 | -11 | 4 | 8 |
31 Dec 18 | 2 | -12 | 3 | 9 |
30 Sep 18 | 3 | -9 | 4 | 9 |
30 Jun 18 | 3 | -6 | 6 | 10 |
31 Mar 18 | 4 | -6 | 7 | 10 |
31 Dec 17 | 6 | -6 | 9 | 11 |
30 Sep 17 | 7 | -8 | 9 | 11 |
30 Jun 17 | 9 | -11 | 9 | 11 |
31 Mar 17 | 7 | -12 | 8 | 10 |
31 Dec 16 | 5 | -12 | 7 | 10 |
30 Sep 16 | 4 | -12 | 6 | 10 |
30 Jun 16 | 3 | -12 | 6 | 10 |
31 Mar 16 | 3 | -10 | 6 | 9 |
31 Dec 15 | 3 | -9 | 5 | 8 |
30 Sep 15 | 2 | -8 | 5 | 7 |
30 Jun 15 | 2 | -7 | 4 | 6 |
31 Mar 15 | 2 | -7 | 3 | 6 |
31 Dec 14 | 2 | -7 | 3 | 5 |
30 Sep 14 | 1 | -7 | 3 | 4 |
30 Jun 14 | 0 | -7 | 3 | 3 |
31 Mar 14 | 0 | -6 | 3 | 2 |
31 Dec 13 | 1 | -5 | 3 | 1 |
30 Sep 13 | 1 | -3 | 3 | 1 |
30 Jun 13 | 1 | -2 | 3 | 0 |
31 Mar 13 | 1 | -1 | 2 | 0 |
31 Dec 12 | 1 | 1 | 2 | 1 |
Guadagni di qualità: KZA is currently unprofitable.
Margine di profitto in crescita: KZA is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: KZA is unprofitable, and losses have increased over the past 5 years at a rate of 22% per year.
Accelerare la crescita: Unable to compare KZA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: KZA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-9.8%).
Rendimento del capitale proprio
ROE elevato: KZA has a negative Return on Equity (-169.83%), as it is currently unprofitable.